BioNTech (BNTX) traded higher Tuesday as investors digested new oncology catalyst momentum following positive Phase 2 results for trastuzumab pamirtecan (T-Pam; BNT323/DB-1303) in HER2-expressing, advanced/recurrent endometrial cancer. The update reinforced BioNTech’s strategy to pivot from volatile COVID-19 vaccine revenue toward a multi-product oncology pipeline. (biospace.com)

The company said the Phase 2 cohort met its primary endpoint and described the efficacy as clinically meaningful in a difficult-to-treat population whose disease progressed after prior therapy. The readout also keeps attention on T-Pam as a potential first approval opportunity within BioNTech’s broader cancer portfolio. (biospace.com)

BioNTech has been working to re-rate its story from a COVID-vaccine cash-flow company to an oncology developer with multiple late-stage shots on goal. In that context, incremental clinical wins can carry outsized weight because they help investors anchor a nearer-term regulatory path for at least one pipeline asset. BioNTech has highlighted 2026 as a heavy year for late-stage trial activity and data readouts across its oncology programs. (investors.biontech.de)

Analyst reaction has been supportive, with at least one major firm citing the T-Pam Phase 2 update in endometrial cancer while lifting its price target and reiterating a Buy view. That combination—fresh clinical data plus near-term target raises—helped fuel the day’s bid in the shares. (tipranks.com)